Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Equity Income (2024 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Income for 2 consecutive years, with -$38634.0 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Income fell 16.04% to -$38634.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$146346.0, a N/A change, with the full-year FY2025 number at -$141007.0, down 39.97% from a year prior.
  • Equity Income was -$38634.0 for Q4 2025 at Outlook Therapeutics, up from -$40419.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$30884.0 in Q2 2025 to a low of -$40419.0 in Q3 2025.